{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.978","value":"2.49"},{"groupId":"OG001","spread":"0.164","value":"1.08"},{"groupId":"OG002","spread":"0.444","value":"0.696"},{"groupId":"OG003","spread":"8.91","value":"7.13"},{"groupId":"OG004","spread":"4.07","value":"2.09"},{"groupId":"OG005","spread":"8.53","value":"3.84"},{"groupId":"OG006","spread":"5.30","value":"3.11"},{"groupId":"OG007","spread":"39.4","value":"12.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"47"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"13"}],"units":"Participants"}],"title":"PBD conjugated Ab: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.80","value":"1.78"},{"groupId":"OG001","spread":"0.348","value":"0.646"},{"groupId":"OG002","spread":"0.205","value":"0.415"},{"groupId":"OG003","spread":"40.6","value":"19.6"},{"groupId":"OG004","spread":"109","value":"17.8"},{"groupId":"OG005","spread":"2.48","value":"0.986"},{"groupId":"OG006","spread":"0.143","value":"0.407"},{"groupId":"OG007","spread":"0.210","value":"0.349"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"40"},{"groupId":"OG005","value":"72"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"PBD conjugated Ab: Cycle 2"},{"categories":[{"measurements":[{"comment":"Standard deviation could not be determined as only one participant had evaluable data.","groupId":"OG000","spread":"NA","value":"1.28"},{"comment":"Standard deviation could not be determined as only one participant had evaluable data.","groupId":"OG003","spread":"NA","value":"0.640"},{"groupId":"OG004","spread":"5.00","value":"2.47"},{"groupId":"OG005","spread":"8.95","value":"3.87"},{"groupId":"OG006","spread":"9.62","value":"7.12"},{"groupId":"OG007","spread":"5.11","value":"2.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"37"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"total Ab: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.71","value":"1.76"},{"groupId":"OG001","spread":"0.309","value":"0.577"},{"groupId":"OG002","spread":"65.5","value":"38.1"},{"groupId":"OG003","spread":"2.06","value":"1.42"},{"groupId":"OG004","spread":"0.660","value":"0.581"},{"groupId":"OG005","spread":"2.91","value":"1.05"},{"groupId":"OG006","spread":"0.161","value":"0.417"},{"groupId":"OG007","spread":"0.187","value":"0.323"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"39"},{"groupId":"OG005","value":"72"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"total Ab: Cycle 2"},{"categories":[{"measurements":[{"comment":"Standard deviation could not be determined as only one participant had evaluable data.","groupId":"OG005","spread":"NA","value":"627"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"SG3199: Cycle 1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"SG3199: Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"40"},{"groupId":"OG005","value":"72"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"13"}],"units":"Participants"}],"description":"CL of Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).\n\nResults for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG000","title":"Part 1: 15 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG001","title":"Part 1: 30 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG002","title":"Part 1: 60 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG003","title":"Part 1: 90 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.","id":"OG004","title":"Parts 1 and 2: 120 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.","id":"OG005","title":"Parts 1 and 2: 150 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.","id":"OG006","title":"Part 1: 200 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 6 week cycle (Q6W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.","id":"OG007","title":"Part 1: 200 μg/kg Q6W"}],"paramType":"MEAN","populationDescription":"Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.","reportingStatus":"POSTED","timeFrame":"Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)","title":"Apparent Clearance (CL) at Steady State for ADCT-402","type":"SECONDARY","unitOfMeasure":"liters/day"}